Can I give 2.5 ml of guaifenesin to an 11-month-old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Guaifenesin Should Not Be Given to an 11-Month-Old Child

Do not administer 2.5 ml of guaifenesin to an 11-month-old infant, as the FDA-approved labeling explicitly states that guaifenesin is not recommended for children under 2 years of age without consulting a physician. 1

FDA Labeling Guidance

  • The FDA drug label for guaifenesin clearly indicates that for "children under 2 years of age" the directive is to "consult a physician" rather than providing a specific dose. 1
  • This age restriction exists because safety and efficacy data in infants under 2 years are insufficient to support routine over-the-counter use. 1

Age-Appropriate Dosing Parameters

  • For children aged 2 to under 6 years, the FDA-approved dose is 2.5 to 5 mL (½ to 1 teaspoonful) every 4 hours, not to exceed 6 doses in 24 hours. 1
  • An 11-month-old falls below this minimum age threshold and therefore does not have an established safe dosing regimen for over-the-counter use. 1

Pharmacokinetic Considerations in Young Children

  • Pediatric pharmacokinetic studies of guaifenesin have been conducted in children aged 2 to 17 years, with age-based doses ranging from 100-400 mg, but these studies specifically excluded infants under 2 years. 2
  • Oral clearance and volume of distribution increase with age due to body size maturation, suggesting that dosing extrapolated from older children may not be appropriate for infants. 2
  • Allometric scaling studies indicate maturation-related changes in drug handling that make infant dosing particularly challenging without specific safety data. 2

Safety Profile and Risks

  • While guaifenesin generally has a favorable safety profile in approved age groups, there is a documented case of fatal overdose in an adult, demonstrating that the drug can cause central nervous system depression and cardiac complications at toxic levels. 3
  • The lack of established dosing for infants under 2 years reflects insufficient data on both efficacy and safety in this vulnerable population. 1

Clinical Recommendation

If your 11-month-old has symptoms requiring treatment (such as chest congestion), consult a pediatrician for appropriate evaluation and management rather than administering over-the-counter guaifenesin. 1 The physician can assess whether treatment is necessary and, if so, can prescribe appropriate therapy with proper dosing guidance specific to your infant's age, weight, and clinical condition. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.